Characterisation of drug release from cubosomes using the pressure ultrafiltration method.
about
Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability.Formulation of dacarbazine-loaded cubosomes-part I: influence of formulation variables.Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization.Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption.In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.Understanding the photothermal heating effect in non-lamellar liquid crystalline systems, and the design of new mixed lipid systems for photothermal on-demand drug delivery.Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting.Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology.Engineering nanomedicines for improved melanoma therapy: progress and promises.Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.Stealth, biocompatible monoolein-based lyotropic liquid crystalline nanoparticles for enhanced aloe-emodin delivery to breast cancer cells: in vitro and in vivo studies.Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins.Lipid nanoparticles for the delivery of poorly water-soluble drugs.Ocular drug delivery - a look towards nanobioadhesives.Lyotropic liquid crystal engineering-ordered nanostructured small molecule amphiphile self-assembly materials by design.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Nanostructured liquid-crystalline particles for drug delivery.Product quality for nanomaterials: current U.S. experience and perspective.Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric techniqueComparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery.Comparative study on the suitability of two techniques for measuring the transfer of lipophilic drug models from lipid nanoparticles to lipophilic acceptors.Oleoylethanolamide-based lyotropic liquid crystals as vehicles for delivery of amino acids in aqueous environment.Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS.Self-assembled liquid crystalline nanoparticles as an ophthalmic drug delivery system. Part I: influence of process parameters on their preparation studied by experimental design.Application of positron annihilation lifetime spectroscopy (PALS) to study the nanostructure in amphiphile self-assembly materials: phytantriol cubosomes and hexosomes.Monoolein cubic phase containing acidic proteinoid: pH-dependent release.Cubic liquid crystalline nanoparticles: optimization and evaluation for ocular delivery of tropicamide.Investigations on the transfer of porphyrin from o/w emulsion droplets to liposomes with two different methods.Converging layer-by-layer polyelectrolyte microcapsule and cubic lyotropic liquid crystalline nanoparticle approaches for molecular encapsulation
P2860
Q33557899-3DFC8E65-7780-453B-9EC5-AA0E5A3AE765Q33573423-542DD028-C5DB-41A8-A88C-5BFC5C551F0EQ34280372-8D896148-DB71-49DB-BA41-E03BBFB08733Q34377929-8108955D-F1CF-417D-8650-E07D241004A2Q35136316-FC8CF36B-2C6A-4F9F-978A-C13E7BD24793Q35344351-BBEF1378-F524-40A3-B0B2-3ADCE67458FDQ36222127-F868F35D-5570-4281-B495-8003877DA7EFQ36237892-59D201DE-D9A0-4B4E-A103-ADF2BFBFE38BQ36350400-B11EFF04-5738-454F-917D-04A7740FFCCDQ36936646-679E268B-E0CE-4DEB-B6DD-6E07DA543AF3Q37214483-847D9A9F-7A2A-4FBA-9748-AFC987988680Q37283473-2213D436-7D2F-4600-BE04-9E545F9AA33AQ37790711-F135E82E-FCBA-4326-9610-46F05C7F2BC8Q37805594-238A24C9-63BF-4D13-8226-289AD4DDA6BEQ37822756-6C615094-107D-4907-B21F-91AC5EDCD63FQ37942744-3BB0036D-1C7F-4983-A799-A45BA1B6F3EDQ38168376-29CFEFAB-BDF1-459A-B83C-F03973D20262Q38184591-A00F31D4-4FC2-4851-A2C0-1B5870097059Q38340318-EA54D2EA-33D3-476A-8FE1-13A5F6165FC0Q38950475-0F8869B7-424F-4A7B-9965-E157C9401298Q41917770-5934D940-908D-4A99-8303-375461489B72Q42075019-6FB1518B-6CD6-41A3-B3E6-FAA1DB85AA1BQ42596094-C76747AC-8800-4E4C-B709-15779210A82FQ43778320-D6822616-CB17-46CE-A24B-80A9B7A2A7F3Q44774296-72452FE5-5947-4394-BC1B-6C43F805C620Q46805373-E855BEFC-911C-4228-BA60-13D563FEE57CQ50444720-05BBDE1E-CA0C-4E06-8E1F-B823DC774839Q53174701-98BFF75D-69D9-4DA4-9C2C-31616A555074Q54688487-0A67595C-4C6C-4486-8F04-6E189A3ACD8FQ57645149-93D3CCB1-B81D-475F-88A5-D8461851DD60
P2860
Characterisation of drug release from cubosomes using the pressure ultrafiltration method.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Characterisation of drug relea ...... essure ultrafiltration method.
@ast
Characterisation of drug relea ...... essure ultrafiltration method.
@en
type
label
Characterisation of drug relea ...... essure ultrafiltration method.
@ast
Characterisation of drug relea ...... essure ultrafiltration method.
@en
prefLabel
Characterisation of drug relea ...... essure ultrafiltration method.
@ast
Characterisation of drug relea ...... essure ultrafiltration method.
@en
P1476
Characterisation of drug release from cubosomes using the pressure ultrafiltration method
@en
P2093
Ben J Boyd
P304
P356
10.1016/S0378-5173(03)00262-X
P407
P50
P577
2003-07-01T00:00:00Z